| pubmed-article:20195673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0002499 | lld:lifeskim |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0282215 | lld:lifeskim |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0055003 | lld:lifeskim |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0746883 | lld:lifeskim |
| pubmed-article:20195673 | lifeskim:mentions | umls-concept:C0250480 | lld:lifeskim |
| pubmed-article:20195673 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20195673 | pubmed:dateCreated | 2010-3-18 | lld:pubmed |
| pubmed-article:20195673 | pubmed:abstractText | Patients with fever and granulocytopenia are at risk of developing severe infection. We performed a prospective, randomized trial to evaluate the efficacy of low-dose cefepime plus amikacin (C-A) compared to low-dose piperacillin/tazobactam plus amikacin (PT-A). Patients received cefepime (2 g/12 h) plus amikacin (15 mg/kg/day) or piperacillin/tazobactam (4 g/500 mg/8 h) plus amikacin. A total of 317 episodes of febrile granulocytopenia in 190 patients were studied (152 in the C-A group, 165 in the PT-A group). A microbiologically documented infection was present in 53 (35%) episodes in the C-A group and 41 (25%) episodes in the PT-A group (p = ns); a clinically documented infection was observed in 39 (26%) and 47 (28%) episodes, respectively. Toxicity was observed in 6 (4%) episodes in the C-A group and in 5 (3%) episodes in the PT-A group. The antibiotic success rate (no change or addition of antibiotics) was recorded in 89 (59%) and 105 (64%) cases, respectively (p = ns). Mortality related to infection was similar in each arm (3.9% vs. 3.6%). Combination therapy of low-dose beta-lactam with an aminoglycoside achieves very good response rates and low rates of toxicity. It might be an attractive option in an environment of increasing resistance among gram-negative bacteria. | lld:pubmed |
| pubmed-article:20195673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20195673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20195673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20195673 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20195673 | pubmed:issn | 1435-4373 | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:MárquezMM | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:GómezII | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:GarauJJ | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:EstradaCC | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:GómezLL | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:QuintanaSS | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:MazzaC JCJ | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:CireraLL | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:EstanyCC | lld:pubmed |
| pubmed-article:20195673 | pubmed:author | pubmed-author:BastúsRR | lld:pubmed |
| pubmed-article:20195673 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20195673 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:20195673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20195673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20195673 | pubmed:pagination | 417-27 | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:meshHeading | pubmed-meshheading:20195673... | lld:pubmed |
| pubmed-article:20195673 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20195673 | pubmed:articleTitle | Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial. | lld:pubmed |
| pubmed-article:20195673 | pubmed:affiliation | Infectious Diseases Unit, Hospital Universitari Mutua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain. lgomez@mutuaterrassa.es | lld:pubmed |
| pubmed-article:20195673 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20195673 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20195673 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
